You are here

Genmab

MorphoSys Settles Patent Lawsuit with Janssen and Genmab

MorphoSys Settles Patent Lawsuit with Janssen and Genmab

CP Wire

Flag link:

MorphoSys Settles Patent Lawsuit with Janssen and Genmab

patent lawsuits

Flag link:

MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab

MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab

CP Wire

Flag link:

MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab

Flag link:

Genmab's blockbuster Darzalex surpasses $2B in sales

Genmab's blockbuster Darzalex surpasses $2B in sales

BioCentury

Multiple Myeloma

Flag link:

Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial

Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial

BioSpace

clinical trials

Multiple Myeloma

Flag link:

Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more

Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more

Endpoints

cancer immunotherapy

Flag link:

Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors

Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors

CP Wire

Seattle Genetics

colorectal cancer

non-small cell lung cancer

pancreatic cancer

head and neck cancer

cervical cancer

tisotumab vedotin

clinical trials

Flag link:

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Xconomy

clinical trials

Flag link:

Danish biotech Genmab hit by ending of trial using key cancer drug

Danish biotech Genmab hit by ending of trial using key cancer drug

Reuters

Flag link:

Genmab hits roadblock in non-Hodgkin lymphoma

Genmab hits roadblock in non-Hodgkin lymphoma

Biopharma Dive

non-Hodgkin's lymphoma

clinical trials

Flag link:

Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

Fierce Pharma

chronic lymphocytic leukemia

Flag link:

Genmab and J&J 'love' partnership as some ponder takeover

Genmab and J&J 'love' partnership as some ponder takeover

Yahoo/Reuters

Flag link:

Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort

Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort

Endpoints

Seattle Genetics

antibody-drug conjugate

tisotumab vedotin

Flag link:

Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger

Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger

Endpoints

Multiple Myeloma

clinical trials

Flag link:

Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years

Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years

Motley Fool

specialty medicines

Flag link:

Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma

Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma

Fierce Pharma

non-Hodgkin's lymphoma

Flag link:

Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand

Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand

Motley Fool

Multiple Myeloma

Flag link:

Gilead licenses bi-specific tech from Danish biotech Genmab

Gilead licenses bi-specific tech from Danish biotech Genmab

BioPharma Dive

Gilead Sciences

Flag link:

Novartis stops PhIII trial of Genmab's Arzerra after buying rights from GSK

Novartis stops PhIII trial of Genmab's Arzerra after buying rights from GSK

Fierce Biotech

pemphigus vulgaris

Flag link:

Pages